GSK3B and Familial prostate cancer: In conclusion, the research on the regulatory mechanism of SLFN5 expression has achieved good results in recent years, such as the breakthrough in the study of the pathway through which SLFN5 affects tumor development, the proposed inhibition of MT3-MMP expression by SLFN5 through the AKT/GSK-3β/β-catenin pathway to inhibit the migration and invasion of cancer cells, and SLFN 5 regulation of LAT 1-mediated mTOR activation in depot resistant prostate cancer regulates LAT 1-mediated mTOR activation, among other findings.